Last updated: July 31, 2026
Moduretic 5-50 is a fixed-dose oral combination of amiloride hydrochloride 5 mg and hydrochlorothiazide 50 mg. Its commercial value is limited by generic availability, mature clinical use, low switching costs, and the absence of a meaningful active patent moat. The product may retain niche demand where clinicians want potassium-sparing and thiazide diuretic activity in one tablet, but it does not present a conventional branded-drug growth opportunity.
The investment case is primarily a low-cost generic manufacturing and distribution thesis. Attractive returns would depend on reliable supply, regional shortages, contract sales, or a differentiated formulation rather than on exclusivity, pricing power, or market expansion.
What is Moduretic 5-50 and how does it work?
Moduretic 5-50 combines:
| Component |
Strength |
Pharmacologic role |
| Amiloride hydrochloride |
5 mg |
Potassium-sparing diuretic; blocks epithelial sodium channels in the distal nephron |
| Hydrochlorothiazide |
50 mg |
Thiazide diuretic; increases sodium and water excretion |
Hydrochlorothiazide produces diuresis and can cause potassium loss. Amiloride reduces potassium excretion and is included to limit thiazide-induced hypokalemia. The combination is used for hypertension and edema associated with congestive heart failure, cirrhosis, and other conditions, subject to local labeling. The U.S. product labeling identifies the combination as an antihypertensive and diuretic product (Merck Sharp & Dohme, 2019).
The 5-50 strength contains a relatively high hydrochlorothiazide dose by modern hypertension standards. Many current treatment strategies favor lower thiazide doses, separate potassium management, or alternative agents. That dosing profile narrows the addressable market but does not eliminate demand in established patients.
What is the FDA and regulatory status of Moduretic 5-50?
Moduretic was approved in the United States as an older prescription product under an original New Drug Application associated with Merck. The product is based on small-molecule active ingredients with long-established regulatory histories. No biologic license application, biosimilar pathway, or complex-device approval is involved.
The primary regulatory characteristics are:
| Regulatory factor |
Assessment |
| FDA product category |
Prescription oral tablet |
| Active ingredients |
Amiloride hydrochloride and hydrochlorothiazide |
| FDA pathway |
Legacy NDA and subsequent generic ANDAs |
| Biologic exclusivity |
Not applicable |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
No current commercial relevance identified |
| Regulatory complexity |
Low to moderate |
| Main approval risk for a generic |
Bioequivalence, chemistry and manufacturing controls, stability, and labeling |
FDA-approved generic products containing amiloride and hydrochlorothiazide can be approved under abbreviated new drug applications if they demonstrate pharmaceutical equivalence and bioequivalence to the reference product or satisfy the applicable regulatory requirements for the relevant listed product. FDA’s Orange Book is the principal source for reference-listed-drug, therapeutic-equivalence, patent, and exclusivity information (U.S. Food and Drug Administration, 2024a).
What patents protect Moduretic 5-50?
No commercially meaningful active composition-of-matter patent protects the Moduretic 5-50 combination today. Amiloride and hydrochlorothiazide are longstanding small molecules, and the original product patents and regulatory exclusivity periods expired many years ago.
The likely historical protection consisted of some combination of:
- Active-ingredient patents for amiloride or hydrochlorothiazide.
- Combination-product claims.
- Tablet formulation or manufacturing claims.
- Labeling and method-of-use claims.
Those rights are no longer a material barrier to ordinary generic entry. Any remaining patent issue would more likely concern a specific reformulated product, manufacturing process, or jurisdiction-specific filing rather than the legacy Moduretic tablet.
| IP category |
Current investment relevance |
| Composition of matter |
Effectively expired |
| Fixed-dose combination |
Expired or commercially non-blocking |
| Tablet formulation |
No known broad barrier to standard generic manufacture |
| Method of use |
No meaningful exclusivity for routine indications |
| Manufacturing process |
Potentially relevant only to a proprietary process |
| Trademark |
May remain registrable in some jurisdictions but does not prevent generic substitution |
Patent status must be checked by jurisdiction because patent expiration, abandonment, maintenance, and regulatory listing practices differ. In the United States, the relevant current status is the absence of a commercially material Orange Book patent or exclusivity barrier for standard amiloride/hydrochlorothiazide tablets based on FDA Orange Book records (U.S. Food and Drug Administration, 2024a).
When does Moduretic 5-50 lose exclusivity?
Moduretic 5-50 has already lost conventional market exclusivity. Its commercial position is therefore determined by generic competition rather than by a future loss-of-exclusivity event.
| Exclusivity type |
Status |
| New chemical entity exclusivity |
Expired |
| Patent exclusivity |
Expired |
| Orphan exclusivity |
Not applicable |
| Pediatric exclusivity |
Not commercially relevant |
| Market exclusivity for the legacy brand |
No current protective period identified |
| Generic substitution |
Available in markets with approved equivalent products |
The key timing question for an investor is not when exclusivity ends. It is whether a supplier can maintain acceptable margins after multiple generic entrants and whether the product remains listed by hospitals, wholesalers, and national formularies.
How many patents cover Moduretic 5-50?
The number of historical patent documents associated with amiloride, hydrochlorothiazide, the combination, or the original brand is not the same as the number of enforceable patents that can block generic entry. For investment purposes, the relevant count of active blocking patents is effectively zero for the legacy product in the United States.
A patent search should separate:
- Expired composition patents.
- Expired combination patents.
- Abandoned applications.
- Process patents with narrow claim scope.
- Formulation patents covering a different dosage form.
- Orange Book-listed patents linked to an approved product.
This distinction prevents overestimating the value of old patent records. A large historical patent family does not create current exclusivity.
What is the Orange Book status of Moduretic 5-50?
The Orange Book remains the controlling U.S. reference for listed drugs, therapeutic equivalence, patents, and regulatory exclusivity. Moduretic’s commercial position is consistent with an off-patent reference product facing generic competition. Investors should not treat the historical brand listing as evidence of current exclusivity.
The relevant diligence points are:
- Whether the brand reference product remains actively marketed.
- Which product is designated as the reference-listed drug.
- Whether approved ANDAs have therapeutic-equivalence ratings.
- Whether any patent or exclusivity code remains active.
- Whether the branded NDA has been withdrawn for safety or commercial reasons.
A withdrawal from commercial marketing is not equivalent to a withdrawal for safety or effectiveness. FDA records distinguish those categories, and that distinction affects the availability of generic approvals and reference-product strategy (U.S. Food and Drug Administration, 2024b).
What formulations are protected by Moduretic 5-50?
The legacy product is an immediate-release oral tablet. There is no established commercial moat around the standard tablet formulation.
Potentially differentiated versions could include:
- Lower-dose hydrochlorothiazide combinations.
- Modified-release tablets.
- Orally disintegrating tablets.
- Unit-dose hospital packaging.
- Combination products with other antihypertensives.
- Formulations designed to reduce tablet burden or improve adherence.
These products would not automatically inherit Moduretic’s brand value. A new formulation would require its own regulatory and intellectual-property strategy. Depending on the change, the sponsor could pursue an ANDA, a 505(b)(2) application, or a conventional NDA. A formulation patent would need commercially meaningful claims and sufficient enforceability to support pricing above commodity-generic levels.
Are there method-of-use patents for Moduretic 5-50?
Routine use in hypertension, edema, and prevention of thiazide-associated potassium loss is not expected to support current exclusivity. Any historical method-of-use patents would be expired or commercially weak.
A new method-of-use opportunity would require a clinically differentiated claim, such as a defined patient population, dosing regimen, or outcome. That strategy would face substantial hurdles:
- Existing clinical experience with both ingredients.
- Limited novelty for routine diuretic use.
- Need for controlled clinical evidence.
- Potentially narrow reimbursement coverage.
- Difficulty preventing physicians from using generic ingredients outside the claimed method.
Method-of-use protection is therefore unlikely to support a large standalone investment in the legacy product.
Which companies are challenging Moduretic 5-50?
The principal competitive threat comes from generic manufacturers rather than from a branded challenger. Depending on the jurisdiction, suppliers may include regional generic companies, contract manufacturers, and multinational generic manufacturers.
Typical competitors in this category include companies that market amiloride/hydrochlorothiazide tablets under generic names or local brands. The competitive field is shaped by:
- Approved manufacturing capacity.
- Wholesaler contracts.
- National tender awards.
- Product availability.
- Drug-shortage conditions.
- Ability to maintain validated supply of both active ingredients.
There is no economically important Paragraph IV litigation story associated with the legacy Moduretic product. Paragraph IV certifications are most relevant when an applicant challenges an unexpired Orange Book patent. With no material blocking patent expected for the standard product, generic entry is more likely to proceed through ordinary ANDA pathways than through high-value patent litigation.
What patent litigation affects Moduretic 5-50?
No material current U.S. patent litigation is associated with the legacy Moduretic 5-50 product in the ordinary commercial sense. Any historical disputes would have limited relevance unless they created an enforceable settlement, supply restriction, or continuing licensing obligation.
For investment diligence, the litigation review should cover:
| Issue |
Current risk assessment |
| Paragraph IV litigation |
Low |
| Preliminary injunction risk |
Low |
| Formulation patent litigation |
Low for the legacy tablet |
| Trade-secret litigation |
Possible only for a proprietary process |
| Antitrust litigation |
Low absent coordinated market conduct |
| Product-liability litigation |
Ongoing operational risk for all suppliers |
| Labeling litigation |
Low but not zero |
The absence of patent litigation does not remove product-liability, manufacturing, recall, or regulatory-compliance risk.
Are there licensing deals for Moduretic 5-50?
A licensing deal is not required to commercialize a standard generic version where the relevant patents and exclusivity have expired. Historical brand commercialization may have involved distribution or regional licensing arrangements, but such agreements would not necessarily provide current economic protection.
A current licensing opportunity would have value only if it delivered one or more of the following:
- Exclusive rights in a territory.
- Guaranteed supply of amiloride or hydrochlorothiazide.
- A differentiated formulation.
- Regulatory approvals in a high-value market.
- Access to hospital or government procurement channels.
- A protected manufacturing process.
An ordinary nonexclusive trademark or distribution license would add limited value because equivalent generic products can compete on price.
How strong is the patent estate for Moduretic 5-50?
The patent estate is weak from an investment perspective.
| Patent-strength factor |
Assessment |
| Remaining term |
None of material commercial significance |
| Claim breadth |
Narrow or expired for historical rights |
| Design-around risk |
High |
| Generic entry barrier |
Minimal |
| Litigation leverage |
Minimal |
| Reformulation opportunity |
Possible but unproven |
| Defensibility |
Low |
The product can generate cash flow in a stable niche, but it cannot support premium valuation based on intellectual property. Any valuation model that applies branded-drug pricing power or a patent-life multiple would overstate the asset’s defensibility.
What generic entry risks exist for Moduretic 5-50?
Generic entry is already the central market condition. The main risks are margin compression and product substitution.
Generic competition can reduce value through:
- Lower average selling prices.
- Pharmacy-level substitution.
- Formulary exclusion.
- Wholesaler concentration.
- Tender-price pressure.
- Inventory write-downs.
- Loss of physician awareness of the brand.
- Buyer preference for separate amiloride and hydrochlorothiazide tablets.
The countervailing opportunity is supply reliability. Older products can experience intermittent shortages because they have low margins, limited suppliers, or constrained active pharmaceutical ingredient capacity. A manufacturer with dependable supply may capture temporary pricing power, but shortage-driven returns are difficult to forecast and can attract new entrants.
How does Moduretic 5-50 compare with separate amiloride and hydrochlorothiazide?
The fixed-dose tablet offers convenience, while separate tablets offer greater dose flexibility.
| Factor |
Moduretic 5-50 |
Separate products |
| Tablet burden |
Lower |
Higher |
| Dose flexibility |
Low |
High |
| Cost |
Usually higher than commodity single ingredients |
Often lower |
| Potassium management |
Built into the product |
Clinician-controlled |
| Titration |
Less flexible |
More flexible |
| Generic competition |
High |
Very high |
| Formulary acceptance |
Variable |
Usually broad |
| Commercial differentiation |
Limited |
Limited |
The product may remain useful for patients stabilized on the combination. New starts may favor separate components, lower hydrochlorothiazide exposure, or alternative antihypertensive regimens.
What is the revenue exposure and investment scenario?
No reliable public financial disclosure isolates Moduretic 5-50 revenue. Merck’s public reporting does not provide a current product-level revenue line for this mature product, and generic manufacturers generally report portfolios rather than product-specific revenue. Revenue should therefore be modeled from prescription volume, net price, market share, and channel mix rather than from historical brand sales.
Base case
The base case is a stable but declining mature-product business:
- Low unit growth.
- Continued generic substitution.
- Limited pricing power.
- Small working-capital requirements.
- Modest regulatory maintenance cost.
- Low research-and-development requirements.
- Declining brand relevance.
This case supports a cash-generative generic product only if manufacturing and distribution costs are low.
Bull case
The bull case depends on:
- A supply disruption among competitors.
- A shortage of equivalent products.
- An exclusive hospital or government contract.
- Regional market entry before competitors.
- A reformulated product with regulatory or channel differentiation.
- A combination strategy bundled with other cardiovascular generics.
The bull case is operational, not patent-driven.
Bear case
The bear case includes:
- Additional generic entrants.
- Permanent price erosion.
- Loss of reference-product status or brand marketing support.
- Supplier failure for either active ingredient.
- Manufacturing observations or product recalls.
- Reduced clinical use of high-dose hydrochlorothiazide.
- Substitution with separate tablets or newer antihypertensive classes.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are more relevant than patent barriers. The product requires validated control of two active ingredients in a stable oral dosage form. Key technical risks include blend uniformity, content uniformity, dissolution, impurity control, tablet stability, packaging, and supply of qualified active pharmaceutical ingredients.
Amiloride is a lower-volume ingredient than hydrochlorothiazide. That imbalance can complicate procurement and increase dependence on a small supplier base. A manufacturer that controls or secures both inputs may have an advantage in tenders and shortage markets.
The product remains relatively straightforward compared with sterile injectables, modified-release systems, inhaled products, or biologics. Its manufacturing barrier is therefore manageable, but its commercial barrier is also low.
What is the generic launch scenario for Moduretic 5-50?
A new entrant would likely follow this sequence:
- Confirm the reference-listed drug and regulatory pathway.
- Establish an approved or approvable formulation.
- Complete bioequivalence and stability work.
- File an ANDA or applicable national generic application.
- Secure qualified API suppliers.
- Obtain manufacturing approval.
- Enter through wholesalers, pharmacies, tenders, or hospital channels.
- Compete on supply reliability and price.
A first entrant may obtain temporary commercial benefits from limited competition or a shortage, but the long-term market is likely to normalize toward generic pricing. No standard patent-based launch delay is expected for the legacy combination.
What are the geographic opportunities for Moduretic 5-50?
The strongest opportunity is likely in markets where:
- Generic substitution is established.
- Combination tablets are reimbursed.
- Hypertension and edema treatment volumes are large.
- Local suppliers are unreliable.
- Government procurement favors low-cost oral medicines.
- Regulatory approval can be obtained without extensive new clinical trials.
The United States offers a regulated but highly competitive market. Europe and other mature markets may offer volume but generally limited margins. Emerging markets may provide higher brand recognition for the original trade name, but pricing, registration, local manufacturing, and tender requirements can materially affect returns.
Trademark rights, reference-product status, and local approval must be reviewed separately in each jurisdiction. U.S. FDA approval does not establish automatic commercial rights elsewhere.
Key Takeaways
- Moduretic 5-50 contains amiloride hydrochloride 5 mg and hydrochlorothiazide 50 mg.
- The product is a mature, off-patent oral combination.
- No meaningful active patent or exclusivity barrier is expected for the standard tablet.
- Paragraph IV litigation and patent-settlement risk are low.
- The principal risks are generic price erosion, substitution, supply disruption, and manufacturing compliance.
- The commercial opportunity is better suited to a low-cost generic or regional distribution strategy than to a branded pharmaceutical investment.
- A differentiated formulation could create value, but it would require new regulatory work and defensible claims.
- Product-specific revenue is not publicly disclosed by major manufacturers, so valuation should use bottom-up volume and net-price assumptions.
- The strongest potential upside comes from supply reliability, tenders, shortages, or geographic expansion.
- The patent estate does not justify a premium valuation.
FAQs
Is Moduretic 5-50 still available?
Availability depends on country, manufacturer, and distributor. Generic amiloride/hydrochlorothiazide products are more relevant to current supply than the original branded product.
Is Moduretic 5-50 protected by a patent?
The legacy combination is not protected by a commercially meaningful unexpired composition or combination patent in the United States.
Can a generic company launch Moduretic 5-50 without a Paragraph IV challenge?
Yes. With no material blocking patent expected for the standard product, a generic applicant would generally pursue the applicable ordinary abbreviated approval route rather than challenge a live patent.
Does Moduretic 5-50 have biosimilar competition?
No. It is a small-molecule drug, not a biologic. Competition comes from generic tablets, not biosimilars.
Is Moduretic 5-50 a good pharmaceutical investment?
It is potentially suitable as a low-cost generic, shortage-supply, tender, or regional distribution asset. It is not attractive as a patent-protected branded-drug investment because exclusivity has expired and pricing power is limited.
References
Merck Sharp & Dohme. (2019). Moduretic-5-50 amiloride hydrochloride and hydrochlorothiazide tablet: Prescribing information. U.S. Food and Drug Administration.
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, 44th ed.: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
